OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
The COVID-19 pandemic has triggered additional considerations to supplier oversight.
Outsourcing method development offers multiple benefits to companies.
Contract manufacturing services for GMP-grade RNA are in demand.
July 08, 2021
LGM Pharma will offer contract analytical testing and stability services to pharmaceutical developers and manufacturers.
July 01, 2021
The extended manufacturing agreement between Pinteon and Lonza enables future clinical production of PNT001, a novel Tau antibody therapeutic that targets Alzheimer's disease and traumatic brain injury.
Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.
CMOs and CDMOs adjust business processes as demand for COVID-19 treatments and non-pandemic related therapies puts pressure on the bio/pharma industry.
June 30, 2021
CDMO Yposkesi will increase its current gene therapy vector capacity through French government’s “Plan de Relance” scheme.
June 24, 2021
The companies have entered into an agreement to develop processes for a novel immunotherapy protein.
The companies will utilize the Cocoon Platform for clinical point-of-care manufacturing.
June 08, 2021
VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.
AGC Biologics has partnered with BioNTech to further supply plasmid DNA starting material from its Heidelberg, Germany, facility for the Pfizer-BioNTech COVID-19 vaccine.
June 01, 2021
The increased number of regulatory filings for cell and gene therapies requires reevaluation of bioassay methods because of their complexity.